Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Nicholas: Still Attractive? - Views on News from Equitymaster
  • E-MAIL
  • A  A  A
  • Apr 30, 2002

    Nicholas: Still Attractive?

    Nicholas Piramal has ended FY02 with a strong financial performance. The figures for FY02 are on a consolidated basis with Rhone Poulenc Rorer (RPR) and hence not exactly comparable. On a merged basis, while sales have recorded a 70% jump, net profit dipped 27% on the back of write off of a one time expenditure of Rs 442 m.

    (Rs m) FY01 FY02 Change
    Sales 5,064 8,662 71.0%
    Other Income 124 374 200.7%
    Expenditure 4,216 7,378 75.0%
    Operating Profit (EBDIT) 848 1,284 51.5%
    Operating Profit Margin (%) 16.7% 14.8%  
    Interest 96 320 233.5%
    Depreciation 139 169 21.5%
    Profit before Tax 737 1,170 58.6%
    Other Adjustments 3 442
    Tax 70 245 249.1%
    Profit after Tax/(Loss) 665 482 -27.4%
    Net profit margin (%) 13.1% 5.6%  
    No. of Shares (eoy) (m) 34.9 38.0  
    Diluted Earnings per share 19.1 12.7  
    P/E (at current price) 22.8  

    The restructuring cost is mainly on account of acquisition of Rhone Poulenc India. This includes a payment for VRS and stock write offs. NPIL sold off the erstwhile Rhone Paithan manufacturing facility to contract manufacturer Encore Pharma for Rs 85 m. During the year, Nicholas also acquired the pharmaceutical division of ICI Ltd as a going concern for a total consideration of Rs 700 m. The acquisition was completed on March 26, 2002 after which date all transactions of the said division has been incorporated in the books of accounts of the Company.

    The Company has changed the accounting policy on treatment of expenditure incurred on VRS. The company used to fully write off the VRS expense in the year of expenditure. The same would now be amortised over a period of 60 months. The profits would had been lower by another Rs 167 m had the company maintained its accounting policy on writing off the entire VRS expense.

    Going forward Nicholas intends to focus primarily on the domestic market. The company is still open to further growth through the in-organic route, strategic alliances and tie-ups. The company believes that the pharma industry would throw exciting acquisitions opportunities as it consolidates in the run up to 2005. Nicholas is investing aggressively in creating a strong marketing infrastructure to prepare itself for in-licensing opportunities from MNC pharma's. Though the company is looking for tie-ups with generic players abroad for manufacturing arrangements, it doesn't intend to aggressively eye the export generic market, quite unlike other domestic pharma majors. The therapeutic areas, which Nicholas caters to, are well diversified. It has launched several new products in last six months in the cardiovascular, anti-diabetic, anti-arthritic and anti-infective segments.

    Read our last report - Are valuations attractive?

    We expect that acquisition synergies would start percolating into financial numbers from the current year. Robust growth numbers (on account of merger without a major strain on balance sheet), a faster payback period, and a broad product basket are expected to make FY03 numbers of the company attractive. We would soon revise our net profit estimates of the company inline with change in accounting policy. However, excluding one time / extra-ordinary expenses, the stock trades at 10x our expected earnings for FY03.



    Equitymaster requests your view! Post a comment on "Nicholas: Still Attractive?". Click here!


    More Views on News

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

    Aug 8, 2017

    Profits plunge due to higher raw material costs.

    Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

    Jun 23, 2017

    Net Profit lower due to exceptional items in the previous year.

    Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

    May 30, 2017

    US markets decline while other geographies grow in the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms


    Aug 18, 2017 (Close)


    • Track your investment in PIRAMAL ENTERPRISES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks



    Compare Company With Charts